NCT00827996View on ClinicalTrials.gov

To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

August 31, 2008

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

adalimumab

Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Florida Academic Dermatology Centers

OTHER